Two antibodies targeting PD-1, nivolumab, and pembrolizumab, and three antibodies targeting PD-L1, durvalumab, atezolizumab, and avelumab, have been approved for B-cell lymphoma (26, 27). This evidence concerns the gene CD274 and B-cell non-Hodgkin lymphoma.